SCHEMBL418489

SCHEMBL418489

COc1cc(C)cc(CN)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.47
MAOB P27338 4/20 0.43
ALDH1A1 P00352 1/20 0.42
TAAR1 Q96RJ0 3/20 0.41
LOXL2 Q9Y4K0 2/20 0.41
CYP19A1 P11511 1/20 0.41
LOX P28300 1/20 0.41
ACHE P22303 1/20 0.40
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
IDO1 P14902 1/20 0.37
AGXT P21549 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18769324 0.86 GRIN2D (0.50) MAOBALDH1A1TAAR1LOXL2CYP19A1
SCHEMBL43448 0.86 ALDH1A1 (0.58) MAOBALDH1A1TAAR1LOXL2CYP19A1
Hydrochloric Acid SCHEMBL2479666 0.84 ALDH1A1 (0.55) MAOBALDH1A1TAAR1LOXL2CYP19A1
SCHEMBL15502971 0.83 TAAR1 (0.56) TACR1MAOBTAAR1CYP19A1
SCHEMBL10175240 0.80 TACR1 (0.45) TACR1MAOBALDH1A1CYP19A1ACHE
SCHEMBL15787170 0.79 PTGS2 (0.47) TACR1MAOBTAAR1CYP19A1
SCHEMBL3507655 0.78 CYP19A1 (0.50) MAOBALDH1A1TAAR1LOXL2CYP19A1
SCHEMBL10204849 0.78 TACR1 (0.51) TACR1MAOBALDH1A1CYP19A1ACHE
SCHEMBL7621664 0.78 TACR1 (0.44) TACR1MAOBALDH1A1CYP19A1ACHE
SCHEMBL12338023 0.78 TACR1 (0.44) TACR1MAOBALDH1A1TAAR1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303999-A1 COMBINATORIAL PLATFORM FOR HIGH-THROUGHPUT POLYNUCLEOTIDE-ENCODED CATALYST DISCOVERY WISCONSIN ALUMNI RESEARCH FOUNDATION 2023-09-28 US disclosed
US-9175038-B2 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2015-11-03 US disclosed
US-8927715-B2 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
US-8901316-B2 Process for preparing aminoadamantyl carbamate derivatives SHIONOGI & CO., LTD. (JP) 2014-12-02 US disclosed
US-20140142044-A1 PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) 2014-05-22 US disclosed
US-8524951-B2 Process for production of hydroxyadamantaneamine SHIONOGI & CO., LTD. (JP) 2013-09-03 US disclosed
US-20130197240-A1 PROCESS FOR PREPARING AMINOADAMANTYL CARBAMATE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2013-08-01 US disclosed
WO-2012170554-A1 N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG KAMENECKA THEODORE MARK (US) 2012-12-13 WO disclosed
US-20120065146-A1 PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) 2012-03-15 US disclosed
US-20110269971-A1 PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE SHIONOGI & CO., LTD. (JP) 2011-11-03 US disclosed
US-20110034455-A1 INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034455-A1 INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 TACR1 3280/4885MAOB 614/4885ALDH1A1 78/4885
US-20130197240-A1 PROCESS FOR PREPARING AMINOADAMANTYL CARBAMATE DERIVATIVES HSD11B1, SRD5A1, ALDH7A1 TACR1 998/4885MAOB 3203/4885ALDH1A1 520/4885
US-20140142044-A1 PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE PLK1, PLK4, PLK3 TACR1 3864/4885MAOB 4213/4885ALDH1A1 4542/4885
US-20120065146-A1 PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE PLK1, PLK2, PLK4 TACR1 4333/4885MAOB 4240/4885ALDH1A1 4782/4885
US-20110269971-A1 PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE HAAO, CYP4A11, CYP4F11 TACR1 1098/4885MAOB 320/4885ALDH1A1 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.